Penumbra, Inc. (PEN)

Market Cap	7.82B
Revenue (ttm)	1.06B
Net Income (ttm)	90.95M
Shares Out	38.70M
EPS (ttm)	2.32
PE Ratio	87.00
Forward PE	70.55
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,738
Open	202.70
Previous Close	201.84
Day's Range	201.18 - 204.11
52-Week Range	180.93 - 348.67
Beta	0.53
Analysts	Strong Buy
Price Target	298.55 (+47.86%)
Earnings Date	May 7, 2024

About PEN

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, S...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Sep 18, 2015
• Employees: 4,200
• Stock Exchange: NYSE
• Ticker Symbol: PEN

Analyst Forecast

According to 11 analysts, the average rating for PEN stock is "Strong Buy." The 12-month stock price forecast is $298.55, which is an increase of 47.86% from the latest price.

Price Target

$298.55

(47.86% upside)

Analyst Consensus: Strong Buy